Abstract:The biosynthesis and release of nitric oxide (NO) and prostaglandins (PGs) share a number of similarities. Two major forms of nitric-oxide synthase (NOS) and cyclooxygenase (COX) enzymes have been identified to date. Under normal circumstances, the constitutive isoforms of these enzymes (constitutive NOS and COX-1) are found in virtually all organs. Their presence accounts for the regulation of several important physiological effects (e.g. antiplatelet activity, vasodilation, and cytoprotection). On the other hand, in inflammatory setting, the inducible isoforms of these enzymes (inducible NOS and COX-2) are detected in a variety of cells, resulting in the production of large amounts of proinflammatory and cytotoxic NO and PGs. The release of NO and PGs by the inducible isoforms of NOS and COX has been associated with the pathological roles of these mediators in disease states as evidenced by the use of selective inhibitors. An important link between the NOS and COX pathways was made in 1993 by Salvemini and coworkers when they demonstrated that the enhanced release of PGs, which follows inflammatory mechanisms, was nearly entirely driven by NO. Such studies raised the possibility that COX enzymes represent important endogenous "receptor" targets for modulating the multifaceted roles of NO. Since then, numerous papers have been published extending the observation across various cellular systems and animal models of disease. Furthermore, other studies have highlighted the importance of such interaction in physiology as well as in the mechanism of action of drugs such as organic nitrates. More importantly, mechanistic studies of how NO switches on/off the PG/COX pathway have been undertaken and additional pathways through which NO modulates prostaglandin production unraveled. On the other hand, NO donors conjugated with COX inhibitors have recently found new interest in the understanding of NO/COX reciprocal interaction and potential clinical use. The purpose of this article is to cover the advances which have occurred over the years, and in particular, to summarize experimental data that outline how the discovery that NO modulates prostaglandin production has impacted and extended our understanding of these two systems in physiopathological events.

Nitric oxide in the gastrointestinal tract: opportunities for drug development

Specificity of Inducible Nitric-Oxide Synthase Inhibitors: Prospects for Their Clinical Therapy.

Progress in inhibitors of nitric oxide synthase

Controllable Nitric Oxide‐Delivering Platforms for Biomedical Applications

Advanced Nitric Oxide Generating Nanomedicine for Therapeutic Applications

Targeted Delivery of Nitric Oxide Triggered by Α-Glucosidase to Ameliorate NSAIDs-induced Enteropathy

Nitric oxide: an old drug but with new horizons in ophthalmology-a narrative review

Recent advances on the roles of NO in cancer and chronic inflammatory disorders

The Dual Role of Reactive Oxygen Species-Generating Nicotinamide Adenine Dinucleotide Phosphate Oxidases in Gastrointestinal Inflammation and Therapeutic Perspectives

Nitric oxide signaling in health and disease

Nitric oxide and the immune response

Title Vascular nitric oxide : Beyond eNOS

Facilitating Nitrite-Derived S-Nitrosothiol Formation in the Upper Gastrointestinal Tract in the Therapy of Cardiovascular Diseases

Polymeric Nitric Oxide Delivery Nanoplatforms for Treating Cancer, Cardiovascular Diseases, and Infection

Exogenous NO Therapy for the Treatment and Prevention of Atherosclerosis

Progress in the Development of Nitric Oxide-Releasing Biomaterials and Their Biomedical Applications

[Advances in the Study of Nitric Oxide-Donating Drugs].

Dysfunctional and Dysregulated Nitric Oxide Synthases in Cardiovascular Disease: Mechanisms and Therapeutic Potential

Nitric oxide for the prevention and treatment of viral, bacterial, protozoal and fungal infections

Modulation of Prostaglandin Biosynthesis by Nitric Oxide and Nitric Oxide Donors

Nitric Oxide-Releasing Biomaterials for Biomedical Applications